Phosphodiesterase (PDE) inhibitors are currently under evaluation as agents that may facilitate the improvement of cognitive impairment associated with Alzheimer's disease. This evidence concerns the gene ALDH7A1 and early-onset autosomal dominant Alzheimer disease.